<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01739439</url>
  </required_header>
  <id_info>
    <org_study_id>12-046</org_study_id>
    <secondary_id>NCI-2012-02729</secondary_id>
    <nct_id>NCT01739439</nct_id>
  </id_info>
  <brief_title>Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery</brief_title>
  <official_title>RT-054: A Phase I Study of Neoadjuvant Hypofractionated Chemoradiation Plus Radiosurgical Boost for Patients With Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of radiosurgery boost following&#xD;
      chemoradiation in treating patients with locally advanced pancreatic cancer that may or may&#xD;
      not be removed by surgery. Drugs used in chemotherapy work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Radiation therapy uses high-energy x-rays to kill tumor cells. Radiosurgery can send x-rays&#xD;
      directly to the tumor and cause less damage to normal tissue. Giving chemotherapy and&#xD;
      radiation therapy together with radiosurgery may kill more tumor cells and allow doctors to&#xD;
      save the part of the body where the cancer started&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of a radiosurgery boost added to&#xD;
      hypofractionated chemoradiation in patients with borderline resectable or unresectable&#xD;
      pancreatic cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the effect of a radiosurgery boost added to hypofractionated chemoradiation&#xD;
      on surgical morbidity (specifically, healing of the surgical anastomoses and abdominal wounds&#xD;
      and late hemorrhage from blood vessels in the field) in patients with advanced borderline&#xD;
      resectable (BLR) or unresectable pancreatic cancer.&#xD;
&#xD;
      II. To evaluate the utility of diffusion-weighted magnetic resonance imaging (MRI) as an&#xD;
      assessment of treatment response after chemoradiation followed by radiosurgery.&#xD;
&#xD;
      III. To determine the feasibility of collecting tissue for immunohistochemistry (IHC)&#xD;
      analysis via endoscopic ultrasound or computed tomography (CT)-guided fine needle aspiration.&#xD;
&#xD;
      IV. To utilize pathologic response rates in dose escalated regions, hypofractionated regions,&#xD;
      and the dose gradient region in between to better characterize the radiobiologic response of&#xD;
      pancreatic cancer to radiation dose escalation.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of radiosurgery.&#xD;
&#xD;
      Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes once weekly and&#xD;
      undergo hyperfractionated intensity-modulated radiation therapy (IMRT) 5 days a week in weeks&#xD;
      1-3. Patients then undergo a single fraction of radiosurgery boost in week 5 and then receive&#xD;
      gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 6-8. Treatment continues in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years,&#xD;
      every 6 months for 2 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Actual">December 1, 2015</completion_date>
  <primary_completion_date type="Actual">December 1, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as the dose level in which 1 out of 6 patients observes dose-limiting toxicity (DLT) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>Week 5</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Acinar Cell Adenocarcinoma of the Pancreas</condition>
  <condition>Duct Cell Adenocarcinoma of the Pancreas</condition>
  <condition>Stage IIB Pancreatic Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (chemoradiation and radiosurgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly and undergo hyperfractionated IMRT 5 days a week in weeks 1-3. Patients then undergo a single fraction of radiosurgery boost in week 5 and then receive gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 6-8. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemoradiation and radiosurgery)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hyperfractionated radiation therapy</intervention_name>
    <description>Undergo hyperfractionated IMRT</description>
    <arm_group_label>Treatment (chemoradiation and radiosurgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Undergo hyperfractionated IMRT</description>
    <arm_group_label>Treatment (chemoradiation and radiosurgery)</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiosurgery</intervention_name>
    <description>Undergo radiosurgery boost</description>
    <arm_group_label>Treatment (chemoradiation and radiosurgery)</arm_group_label>
    <other_name>radiation surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diffusion-weighted magnetic resonance imaging</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemoradiation and radiosurgery)</arm_group_label>
    <other_name>diffusion-weighted MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically-confirmed pancreatic adenocarcinoma&#xD;
&#xD;
          -  For the initial dose escalation study, patients must have locally advanced /&#xD;
             unresectable pancreatic cancer; these are defined as follows:&#xD;
&#xD;
               -  No distant metastases&#xD;
&#xD;
               -  Hepatic artery encasement&#xD;
&#xD;
               -  Superior mesenteric artery (SMA) encasement &gt; 180 degrees&#xD;
&#xD;
               -  Any celiac axis abutment&#xD;
&#xD;
               -  Unreconstructable superior mesenteric vein (SMV)/portal occlusion&#xD;
&#xD;
               -  Aortic invasion or encasement&#xD;
&#xD;
               -  Metastases to lymph nodes beyond the field of resection&#xD;
&#xD;
          -  For the expansion phase, patients must have borderline resectable or locally advanced&#xD;
             / unresectable pancreatic cancer; these are defined as follows:&#xD;
&#xD;
               -  No distant metastases&#xD;
&#xD;
               -  At least 45 degree abutment of the hepatic artery or SMA&#xD;
&#xD;
               -  Any celiac axis abutment&#xD;
&#xD;
               -  Near complete occlusion of the SMV or portal vein&#xD;
&#xD;
               -  Unreconstructable or reconstructible SMV/portal occlusion&#xD;
&#xD;
               -  Aortic invasion or encasement&#xD;
&#xD;
               -  Metastases to lymph nodes beyond the field of resection&#xD;
&#xD;
          -  Patients must have evaluable disease&#xD;
&#xD;
          -  Women of childbearing potential must be non-pregnant (negative pregnancy test within&#xD;
             72 hours prior to radiation simulation, postmenopausal woman must have been&#xD;
             amenorrheic for at least 12 months to be considered of non-childbearing potential) and&#xD;
             nonlactating, and men and women must be willing to exercise an effective form of birth&#xD;
             control (abstinence/contraception) while on study and for 3 months after therapy&#xD;
             completed&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status determined to be between&#xD;
             0 and 1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/ul&#xD;
&#xD;
          -  Platelets (PLT) &gt;= 100,000/ul&#xD;
&#xD;
          -  Subjects must sign a written informed consent and Health Insurance Portability and&#xD;
             Accountability Act (HIPAA) consent prior to performance of study-specific procedures&#xD;
             or assessments and must be willing to comply with treatment and follow up&#xD;
&#xD;
          -  Bilirubin less then 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 3 x ULN&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had any prior therapy for pancreatic cancer&#xD;
&#xD;
          -  Concurrent chemotherapy or biologic therapy&#xD;
&#xD;
          -  A history of ataxia telangiectasia or other documented history of radiation&#xD;
             hypersensitivity&#xD;
&#xD;
          -  Scleroderma or active connective tissue disease&#xD;
&#xD;
          -  Active inflammatory bowel disease&#xD;
&#xD;
          -  Serious, active infections requiring treatment with IV antibiotics&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Meyer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 29, 2012</study_first_submitted>
  <study_first_submitted_qc>November 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2012</study_first_posted>
  <last_update_submitted>July 26, 2019</last_update_submitted>
  <last_update_submitted_qc>July 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Acinar Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

